TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: proportion of 'at risk' components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: short-term memory improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Progression to diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Dysuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Frequency of urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Flank pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of hand dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quality-adjusted life-years gained
Endpoint domain: Life impact
Primary endpoint: Agreement on revascularization strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔHbA1c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GE-related hospitalization frequency
Endpoint domain: Adverse events/effects
Primary endpoint: GE-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: median score of patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of samples with poor prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of AB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiopulmonary fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavioral symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Best-corrected visual acuity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal sensitivity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of normal NBNA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of normal results in the CDCC test (PDI and MDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glycemic Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nocturnal pouch pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Large pressure wave amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pouch pressures after evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of mirabegron due to symptom cessation
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-Free Survival (PFS) prolongation
Endpoint domain: Mortality/survival
Primary endpoint: Mean AUC(infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: stiffness level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: enhancing physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete abortion rate
Endpoint domain: Mortality/survival
Primary endpoint: Insulin dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of clinical parameters (PI, GI, PBI, PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hBD-2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sensory pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in daily activities and patient functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in SF-36 physical component scores (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in SF-36 mental component scores (MCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: combined risk of death, MI, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Ratio of superior to inferior quadrant thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of superior to nasal quadrant thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: logMAR visual acuity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patency rates of BBAVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Complication rates of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Complication rates of thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: improvements in urgency episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful cannulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: First pass cannulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of difficult cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean cardiac index after cardiopulmonary bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean troponin I level at 24 h after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in physical and psychological symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal treadmill walking distance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain-free walking distance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-min walk improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for vegetables
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neophobia in food choices
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: clinical pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of corneal abrasions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: participant-reported maximum pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≤4 headache days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean ratio (GMR) of C(max) for R- and S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean ratio (GMR) of AUC(0-∞) for R- and S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean ratio (GMR) of AUC(0-120 h) for PT and INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VLPP (Valsalva Leak Point Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MUCP (Maximum Urethral Closure Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of urinary AFB‐N(7)‐guanine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in heart rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in mean arterial pressure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bioavailability of oral TMP and SMX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of high calorie snack purchases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight gain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative frequency of mammograms with abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative breast biopsy frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity for cancer detection
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of ventricular arrhythmias during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VO2peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of participants achieving ≥175 min·wk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-density lipoprotein (LDL) cholesterol decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High-density lipoprotein (HDL) cholesterol increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gametocyte clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rey Auditory‐Verbal Learning Test immediate recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual search test evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rey‐Osterrieth Complex Figure copy evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Renal failure incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Treatment cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival in patients with pulmonary hypertension (PH)
Endpoint domain: Mortality/survival
Primary endpoint: Inflammatory markers (CRP, interleukin-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hepatic enzyme concentrations (GGT, ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LBMD (Lumbar Bone Mineral Density)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific Activity Scale (SAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma BNP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with acute attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Days of patients with acute attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood CD4 and CD4/CD8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of musculoskeletal disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Major gastrointestinal bleeding (GIB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: lower symptoms of pathological health anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of a symptomatic hypoglycemic episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24‐h mean HRV measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first drink
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in DBP from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in SBP from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gastroduodenal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain level (VAS rest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to request first dose of analgesic drug
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: hs-CRP level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LVEF improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial scar size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median time to treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of dendritic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of fibroblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of satellite cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VEF1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: immune response (varicella antibody titers ≥5 gpELISA units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of any exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean adjusted reliever medication use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Stroke Specific Quality of Life scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of prescription medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in frequency of complex partial seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pain parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decision conflict
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: satisfaction with the process
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Ease of care categorization
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Cost effectiveness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Moisture of the placode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental cost-effectiveness ratio (ICER)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: High-risk HPV detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: risk of exacerbation of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased alveolar bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCP satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recurrences of AF and atrial flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autistic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse events resulting from the switch from an AED brand to generic formulation
Endpoint domain: Adverse events/effects
Primary endpoint: hazard ratio for recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of Grade 2 or worse late rectal toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Geometric mean antibody titers to pertussis antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lactate levels at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative serum sodium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptomatic venous thromboembolism at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: major bleeding at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Incident IADL disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shivering threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: core hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: support
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intraoperative culture results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative rate of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ghrelin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: stent clogging-free survival
Endpoint domain: Mortality/survival
Primary endpoint: risk of stent occlusion
Endpoint domain: Mortality/survival
Primary endpoint: Change in EDSS score at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Serious cardiopulmonary toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of clinical malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital stay duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: NPY secretory capacity in response to ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Error rate for the total AP2 score
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the exogenous serum insulin curve from 0 to 6 h (AUC(0-6 h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximal serum concentration of insulin (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to maximal serum concentration of insulin (t(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: VAS and SNOT-22 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal NO concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of pain attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of pain attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac events (MACE)
Endpoint domain: Mortality/survival
Primary endpoint: Composite of death or myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Target lesion revascularization (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Central macular thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes